Related Experiment Video

Updated: Feb 25, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.7K

Decrease in stathmin expression by arsenic trioxide inhibits the proliferation and invasion of osteosarcoma cells via

Tao Feng1, Jun Xu1, Ping He1

  • 1Clinical Laboratory, The Children's Hospital of Suzhou University, Suzhou, Jiangsu 215025, P.R. China.

Oncology Letters
|August 10, 2017
PubMed

Insights

Arsenic trioxide and doxorubicin combination therapy inhibits osteosarcoma (OS) cell invasion by downregulating stathmin. This treatment targets the MAPK pathway, offering new insights into OS metastasis mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Osteosarcoma (OS) is a common pediatric bone cancer with high metastasis rates.
  • Stathmin expression is implicated in cancer cell proliferation and invasion.
  • Adriamycin (ADM)-resistant OS cells exhibit increased stathmin levels.

Purpose of the Study:

  • To investigate the role of stathmin in osteosarcoma cell invasion.
  • To elucidate the mechanism by which arsenic trioxide (As2O3) and ADM inhibit OS metastasis.

Main Methods:

  • Western blot analysis to assess stathmin expression.
  • Lentiviral-mediated shRNA to silence stathmin.
  • Transwell assays to evaluate cell migration and invasion.
  • Xenograft nude mouse models to assess tumor growth in vivo.

Main Results:

  • Stathmin knockdown significantly suppressed migration and invasion in ADM-resistant OS cells.
  • As2O3 combined with ADM inhibited OS cell migration and invasion.
  • The combination treatment modulated MAPK signaling pathways and E-cadherin expression.
  • Stathmin knockdown reduced tumor growth and increased E-cadherin in vivo.

Conclusions:

  • As2O3 and ADM inhibit stathmin-mediated osteosarcoma invasion through the MAPK pathway.
  • Targeting stathmin offers a potential therapeutic strategy for OS metastasis.
  • Understanding stathmin's role provides insights into OS progression and treatment.
Keywords:
E-cadherinMAPK pathwayarsenic trioxideosteosarcoma metastasisstathmin

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.6K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K